Ceritinib (Zykadia)

Ceritinib at a glance

Ceritinib's verified brand is Zykadia. It belongs to a group of targeted medicines called ALK inhibitors. The usual current starting dose is 450 mg once daily with food. The US and European information reviewed describes 150 mg capsules and 150 mg tablets, so a usual 450 mg dose contains three units of the prescribed formulation. Your actual prescription may use a lower dose.

Diarrhoea, nausea, vomiting, abdominal discomfort and tiredness are important possible effects. Less obvious changes can affect the liver, glucose, pancreatic enzymes or heart rhythm, which is why tests matter even when you feel well. New breathing problems also need prompt attention.

Ceritinib is normally taken every day, without a routine weekly break. Treatment may be paused, reduced or stopped because of side effects or changes in cancer control. Do not make these changes yourself or restart a medically prescribed pause without advice.

How ceritinib works

ALK stands for anaplastic lymphoma kinase. It is a protein involved in cell signalling. Certain alterations in tumour cells can produce an abnormal ALK signal that helps those cells grow. Ceritinib interferes with ALK activity, aiming to slow or control cancer growth. It is a tyrosine kinase inhibitor, not conventional chemotherapy or a checkpoint immunotherapy.

The word targeted does not mean that only cancer cells can be affected. Ceritinib can also interfere with normal body functions. Its effects on the digestive system, liver, blood glucose and heart make safety monitoring essential. Taking tablets at home therefore remains a supervised cancer treatment.

A relevant tumour result makes the treatment worth considering in the appropriate clinical situation; it does not guarantee a response. Scans, symptoms and other assessments help establish whether treatment is helping. You do not need to experience side effects for the medicine to have an effect.

How the team decides whether it is suitable

Your team checks the diagnosis and the tumour's ALK result, together with previous treatment, current health and the applicable prescribing information. Ask what test was used, whether the result is clear and how it affects the proposed plan. Tumour testing and testing for inherited family risk answer different questions; an ALK tumour finding does not by itself establish an inherited condition.

Tell the team about heart rhythm problems, fainting, a slow pulse, congenital long QT syndrome, heart failure, liver disease, diabetes, pancreatitis or previous treatment-related lung inflammation. These issues may affect suitability, starting dose or the monitoring plan. Severe liver impairment requires specific dose consideration.

Kidney problems, poor food intake and ongoing vomiting or diarrhoea also matter. They can affect hydration, blood salts and the ability to follow food instructions. A prescription that suited another patient may not suit you. Let the team know about practical difficulties before the first supply is issued.

Before treatment starts

Blood tests usually include liver function, kidney function, blood counts and blood salts. Fasting glucose should be checked before treatment. Amylase and lipase, enzymes related to the pancreas, should also be assessed. If pregnancy is possible, pregnancy status needs checking before starting.

Your pulse and blood pressure are assessed. An electrocardiogram, or ECG, records the heart's electrical activity; it is especially important if you have relevant heart problems, abnormal blood salts or medicines that affect heart rhythm. Tell the clinician about unexplained blackouts or a family history of a serious inherited rhythm problem.

Bring a complete list of medicines, including inhalers, heartburn remedies, antibiotics, painkillers, vitamins and herbal products. The pharmacist should check it before treatment and whenever anything changes. Some anti-sickness medicines also affect heart rhythm, so use the anti-sickness plan selected for you rather than adding a product independently.

Before leaving, make sure you know the dose, meal routine, next blood-test date and whom to contact outside clinic hours. Ask for instructions for diarrhoea and vomiting. A simple written record is useful if a family member helps with medicines or if several services are involved in your care.

How to take ceritinib

Daily dose and food

The usual current starting dose is 450 mg once daily with food, at approximately the same time each day. European information allows a light meal through to a full meal. You do not need to force a large or fatty meal, but taking the medicine without food is not the same routine.

You may find older information describing 750 mg on an empty stomach. Do not combine that dose with the current food instructions. European information retains a medically supervised alternative for some people who cannot eat because of another medical condition, but it requires a different prescription. Do not alternate fed and fasted dosing or calculate a conversion yourself. Contact the team if you cannot eat.

Swallow the prescribed tablets or capsules whole with water. Do not chew or crush them. If swallowing becomes difficult or you use a feeding tube, speak to the oncology pharmacist before attempting to open a capsule, disperse a tablet or mix medicine into food. A safe alternative needs an individual plan.

The reviewed dose-reduction steps are 300 mg once daily with food and then 150 mg once daily with food. A reduction is a clinical decision to manage tolerability; it is not an instruction to split tablets or take doses on alternate days. Check the new written prescription each time the plan changes.

Missed doses and vomiting

The decision about a missed dose depends on how soon the next dose is due. If the next dose is less than 12 hours away, skip the missed dose. If it is 12 hours or more away, the European patient leaflet says to take the missed dose, then return to the usual schedule. Follow your own supplied instructions and ask the pharmacist if the timing is uncertain. Never double a dose.

If you vomit after taking ceritinib, do not take another dose to replace it. Take the next scheduled dose unless the team gives different advice. Repeated vomiting, inability to keep drinks down, dizziness or reduced urine needs prompt contact, because dehydration and disturbed blood salts may require treatment.

If you take too much, or another person accidentally takes your medicine, contact a doctor or hospital immediately. Keep the pack and dose details available; do not wait for symptoms.

Storage and handling

Keep the medicine in its original packaging, safely away from children and pets. Follow the temperature and storage instructions on your own pack, and avoid excessive heat and moisture. Ask the pharmacist about storage during hot-weather travel rather than leaving a supply in a parked vehicle.

Wash your hands after handling the medicine. Caregivers should avoid direct contact with tablets or capsules and ask the pharmacy how to help safely. Return unused medicine through the hospital or pharmacy route. Do not share tablets or use a leftover supply with an outdated dose.

Monitoring and checking treatment response

Liver monitoring differs between the reviewed labels. US information recommends liver blood tests at least monthly and when needed. European information recommends tests before treatment, every two weeks for the first three months, and monthly afterwards. Abnormal results require more frequent checks. Follow the schedule chosen for your product and circumstances.

Fasting glucose and pancreatic enzymes are checked before treatment and periodically afterwards as clinically needed. Diabetes, steroid use, symptoms or abnormal readings may justify closer glucose monitoring. There is no single fixed weekly glucose schedule in these labels that applies to every patient. Ask whether you need a home glucose meter and which readings should prompt a call.

Pulse and blood pressure should be checked regularly. ECGs and blood salts are monitored particularly in people with risk factors for rhythm problems. Vomiting, diarrhoea and dehydration can disturb potassium and other salts, increasing the importance of these checks. Do not start electrolyte supplements without advice.

Blood counts, kidney tests, weight, food intake and symptoms also help the team assess safety. Planned scans or other disease assessments address cancer control. A blood test can show an important side effect before symptoms appear; feeling well is not a reason to miss monitoring.

Common side effects and practical care

Diarrhoea and abdominal discomfort

Report diarrhoea early and use the anti-diarrhoea medicine prescribed for you. Note how often you pass loose stools compared with your usual pattern, whether you have cramps and whether a stoma is more active. Drink regularly within any fluid limits set for heart or kidney problems. Ask which rehydration drinks are suitable.

Contact the hospital promptly for persistent symptoms, diarrhoea at night, worsening cramps, blood in stools, reduced urine or difficulty drinking. Severe or intolerable digestive symptoms that do not respond to supportive treatment may require a treatment pause and lower dose. Do not keep increasing home remedies while symptoms deteriorate.

Mild abdominal discomfort still deserves discussion. Severe, persistent upper-abdominal pain is different and needs urgent assessment, particularly with vomiting or pain spreading to the back. Pancreatitis is one possible cause, and it cannot be diagnosed safely from symptoms alone.

Nausea, vomiting and appetite changes

Take prescribed anti-sickness treatment as instructed. Small, regular meals and sips of fluid may be easier to manage than a large meal. Tell the team if nausea prevents eating with ceritinib or if vomiting continues despite treatment. They can review supportive medicines, hydration and the next dose.

Track weight if advised and ask for dietetic support when intake falls. Do not try to solve poor appetite by moving ceritinib to an empty-stomach routine yourself. Difficulty swallowing, heartburn or pain on swallowing also needs advice, especially before starting an over-the-counter acid remedy.

Tiredness, anaemia and constipation

Allow time for rest and manageable activity. A sudden change in energy, breathlessness or dizziness can reflect anaemia, dehydration, a rhythm problem or another illness. Report it rather than assuming it is ordinary treatment fatigue. Avoid driving when sleepy, faint or otherwise unsafe.

Constipation can occur too, sometimes influenced by supportive medicines. Gentle movement, suitable fluids and an individual laxative plan may help. Marked swelling of the abdomen, severe pain or vomiting with inability to pass stool or gas needs urgent assessment rather than simply more laxative.

Skin and other changes

Report rash, dry or itchy skin. Gentle cleansing and an unperfumed moisturiser can reduce irritation. Ask before using steroid creams or other medicated products. A widespread blistering rash, facial swelling or breathing difficulty needs urgent medical assessment.

Ceritinib can increase sensitivity to sunlight. Avoid prolonged sun exposure, use sunscreen and wear protective clothing during treatment.

Report new vision changes and do not drive if vision is affected. Swelling, unusual bruising, fever or other symptoms also deserve attention, even if they are not described here. Your team needs to assess the whole clinical picture, including other medicines and illnesses.

Less common but important side effects

Liver injury

Ceritinib can injure the liver. Warning symptoms include yellow skin or eyes, dark urine, reduced appetite, pain on the right side of the upper abdomen, unusual tiredness or easy bruising. Contact the hospital immediately. Blood tests may detect injury before you notice a problem.

Treatment may need to be withheld, restarted at a lower dose or permanently stopped, depending on the findings. Do not try to protect the liver with herbal supplements; some can themselves damage the liver or alter ceritinib levels. Have every product checked.

Lung inflammation

New or worsening cough, breathlessness or fever needs immediate contact with the treating hospital. Ceritinib can cause inflammation of lung tissue, called pneumonitis or interstitial lung disease. Infection, blood clots and the cancer itself are other possible explanations, so symptoms need investigation.

If drug-related lung inflammation is suspected, do not take another dose until the treating team has urgently assessed you and given instructions. Severe breathing difficulty needs emergency care without waiting for a callback. Confirmed treatment-related pneumonitis requires permanent discontinuation in the reviewed labels; do not restart after such a diagnosis on your own.

Heart rhythm changes and a slow pulse

Ceritinib can slow the heart rate or prolong the QT interval, part of the heart's electrical recovery cycle. These changes can occasionally cause dangerous rhythms. Report palpitations, unusual dizziness, light-headedness or a markedly slow pulse promptly. Fainting, collapse, chest pain or severe breathlessness requires emergency assessment.

The team may pause treatment, correct blood salts and review interacting medicines. Do not stop a heart medicine independently: the prescribers need to coordinate any changes. A normal pulse reading at home does not rule out an electrical rhythm problem.

High glucose, pancreatitis and kidney problems

Raised glucose can cause thirst, frequent urination, hunger, blurred vision or unusual tiredness. Report these promptly, including if you have never had diabetes. Severe weakness, confusion or vomiting with marked thirst needs urgent assessment. Diabetes medicines may need starting or adjusting, with continued monitoring.

Pancreatitis means inflammation of the pancreas. Severe persistent upper-abdominal pain, sometimes spreading to the back and accompanied by vomiting, needs urgent care. Amylase or lipase may rise without pancreatitis, so a test result needs clinical interpretation rather than a self-diagnosis.

Kidney test changes can occur, and dehydration adds further risk. Reduced urine, faintness or inability to keep fluids down should be reported promptly. These symptoms may require blood tests and fluids rather than waiting for the next routine appointment.

Other medicines, supplements and vaccinations

Ceritinib has important interactions involving liver enzymes, especially CYP3A. Strong inhibitors can raise its level, while strong inducers can reduce it. These combinations should be avoided; if a strong inhibitor is unavoidable, the specialist must adjust ceritinib. Examples requiring checking include some antifungal or antiviral medicines, rifampicin, carbamazepine, phenytoin and St John's wort. Avoid grapefruit and grapefruit juice.

Ceritinib can also raise levels of other medicines, including some sedatives, pain medicines, cholesterol medicines and blood thinners. Warfarin may require more frequent INR tests. Drugs that slow the pulse or prolong the QT interval need particular attention. This includes some anti-sickness medicines and antibiotics. Do not assume a medicine is safe because it is familiar or available without prescription.

Heartburn treatment needs a specific plan. European information advises caution with proton pump inhibitors because ceritinib exposure may decrease. It describes possible timing approaches for H2 blockers and antacids, but these do not prove every combination is harmless. US information interprets the available acid-suppression data differently. Ask the oncology pharmacist to choose the product and timing; do not stop a prescribed acid medicine or simply separate all medicines by two hours yourself.

Ask about flu, COVID-19 and travel vaccines. Timing and suitability, especially for live vaccines, depend on the complete treatment plan and immune function. Tell any dentist, emergency clinician or other prescriber about ceritinib before treatment or new medicines are given.

Everyday life during treatment

Choose a repeatable meal and dose time. Record doses if memory, shift work or caregiver changes make it difficult to keep track. Before travel, discuss time-zone adjustments, carry enough medicine and know where to obtain help. Do not alter the daily schedule just to fit a journey.

Work and exercise plans can be adapted to how you feel. Gentle activity may help fatigue, but stop and seek advice if activity brings unusual breathlessness, chest symptoms or dizziness. Ask for help with transport while symptoms or tests make driving unsafe.

Food restrictions, appetite changes and worries about scans can affect daily life. Tell the team about these problems; practical support may be as useful as another information leaflet. Ask about alcohol in light of liver tests and other medicines. There is no special diet or supplement proven to replace the prescribed treatment.

Fertility, contraception, pregnancy and breastfeeding

Ceritinib may harm a developing baby. Pregnancy testing is needed before treatment when pregnancy is possible. Discuss reliable contraception before the first dose, and tell the team immediately about a pregnancy or possible pregnancy during treatment or the precaution period.

US guidance requires effective contraception during treatment and for six months after the last dose for patients who can become pregnant. It advises male patients with partners who can become pregnant to use condoms during treatment and for three months afterwards. European guidance gives a three-month post-treatment contraception period for women. Obtain a written plan for your supplied product rather than choosing the shorter interval yourself.

European information warns that oral contraceptives may become less effective. Ask for an appropriate additional or alternative method; vomiting or diarrhoea can also complicate pill use. Do not assume irregular periods or reduced fertility prevents pregnancy.

Do not breastfeed while taking ceritinib. US guidance continues this restriction for two weeks after the final dose. European information requires a choice between breastfeeding and treatment but does not specify the same post-treatment interval. Agree a restart date with the treating team. Human fertility effects are uncertain; discuss preservation options before treatment if future parenthood matters to you.

After treatment stops or changes

Continue any blood tests and follow-up arranged after stopping. Liver, glucose, digestive or other problems may still need monitoring and treatment. Report new or persistent symptoms rather than assuming the final tablet ends all risk. Continue contraception and breastfeeding precautions for the agreed period.

If the dose changes, ask for an updated written plan and separate or return superseded supplies as advised. A temporary pause should have clear conditions for restarting. Do not restart because a symptom seems better or because a scan appointment is approaching.

Ask what happens next: who manages unresolved side effects, when the next assessment is due and whether supportive medicines should continue. Diabetes, anti-sickness, bowel or heart medicines may need reassessment, but changes should be coordinated with the clinician who prescribed them.

Frequently asked questions